High seroprevalence of *Leishmania infantum* is linked to immune activation in people with HIV: a two-stage cross-sectional study in Bahia, Brazil

Laise de Moraes^{1,2}, Luciane Amorim Santos^{1,2,3}, Liã Bárbara Arruda⁴, Maria da Purificação Pereira da Silva⁵, Márcio de Oliveira Silva⁵, José Adriano Góes Silva^{1,2,5}, André Ramos⁵, Marcos Bastos dos Santos², Felipe Guimarães Torres², Cibele Orge², Antonio Marcos Teixeira², Thiago Vieira², Laura Ramírez⁶, Manuel Soto⁶, Maria Fernanda Rios Grassi^{2,3}, Isadora Cristina de Siqueira², Dorcas Lamounier Costa⁷, Carlos Henrique Costa⁷, Bruno de Bezerril Andrade^{2,3}, Kevan Akrami^{1,2}, Camila Indiani de Oliveira^{1,2,3}, Viviane Sampaio Boaventura^{1,2,8}, Manoel Barral-Netto^{1,2}, Aldina Barral^{1,2*}, Anne-Mieke Vandamme^{9*}, Johan Van Weyenbergh^{9*}, Ricardo Khouri^{1,2,9}

1 Programa de Pós-graduação em Ciências da Saúde, Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, Brazil.

2 Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.

3 Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil.

4 Centre for Clinical Microbiology, Division of Infection & Immunity, University College London, London, United Kingdom.

5 Centro Estadual Especializado em Diagnóstico, Assistência e Pesquisa, Secretaria de Saúde do Estado da Bahia, Salvador, Brazil.

6 Departamento de Biología Molecular, Facultad de Ciencias, Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Madrid, Spain.

7 Laboratório de Leishmanioses, Instituto de Doenças Tropicais Natan Portella, Universidade Federal do Piauí, Teresina, Brazil.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 8 Hospital Santa Izabel, Salvador, Brazil.

27 9 Department of Microbiology, Immunology and Transplantation, Rega Institute for

28 Medical Research, Clinical and Epidemiological Virology, KU Leuven, Leuven,

29 Belgium.

30

31 *equal contribution

32

33 **Short title:** *Leishmania* seropositivity linked to immune activation in people with HIV

ABSTRACT

Background: Visceral leishmaniasis is an opportunistic disease in HIV-1 infected individuals, although not yet recognized as a determining factor for AIDS diagnosis. The growing geographical overlap of HIV-1 and *Leishmania* infections is an emerging challenge worldwide, as co-infection increases morbidity and mortality for both. Here, we determined the prevalence of people living with HIV (PWH) with a previous or ongoing infection by *Leishmania infantum* in Bahia, Brazil and investigated the virological and immunological factors associated with co-infection.

Methodology and Principal Findings: We adopted a two-stage cross-sectional cohort (CSC) design (CSC-I, n=5,346 and CSC-II, n=317) of treatment-naïve HIV-1-infected individuals in Bahia, Brazil. In CSC-I, samples collected at the time of HIV-1 diagnosis between 1998 and 2013 were used for serological screening for leishmaniasis by an in-house immunoassay (ELISA) with SLA (Soluble Leishmania Antigen), resulting in a prevalence of previous or ongoing infection of 16.27%. Next, 317 PWH were prospectively recruited from July 2014 to December 2015 with collection of sociodemographic and clinical data. Serological validation by two different immunoassays confirmed a prevalence of 15.46% and 8.20% by anti-SLA, and anti-HSP70 serology, respectively, whereas 4.73% were double-positive (DP). Stratification of these 317 individuals in DP and double-negative (DN) revealed a significant reduction of CD4⁺ counts and CD4⁺/CD8⁺ ratios and a tendency of increased viral load in the DP group, as compared to DN. No statistical differences in HIV-1 subtype distribution were observed between the two groups. However, we found a significant increase of CXCL10/IP-10 ($p=0.0076$) and a tendency of increased CXCL9/MIG ($p=0.061$) in individuals with DP serology for *L. infantum*, demonstrating intensified immune

activation in this group. These findings were corroborated at the transcriptome level in independent *Leishmania*- and HIV-1-infected cohorts (Swiss HIV Cohort and Piaui Northeast Brazil Cohort), indicating that *CXCL10* transcripts are shared by the IFN-dominated immune activation gene signatures of both pathogens and positively correlated to viral load in untreated PWH.

Conclusions/Significance: This study demonstrated a high prevalence of PWH with *L. infantum* seropositivity in Bahia, Brazil, linked to IFN-mediated immune activation and a significant decrease in CD4⁺ levels. Our results highlight the urgent need to increase awareness and define public health strategies for the management and prevention of HIV-1 and *L. infantum* co-infection.

AUTHOR SUMMARY

More than 1 billion people live in areas endemic for leishmaniasis and are at risk of infection, which includes one third of the 38 million people living with HIV (PWH) worldwide. Leishmaniasis is a neglected tropical disease caused by infection with *Leishmania* parasites, transmitted by bites from infected sand flies. HIV/*Leishmania* co-infection is increasing worldwide, especially in Southern Europe and Brazil, due to both human and ecological factors (migration, climate change, deforestation). This study demonstrates that a worryingly high number (one out of 6) of PWH in Bahia (Northeast Brazil) show previous or ongoing infection with the parasite *Leishmania infantum*, determined by antibodies detection against this parasite in PWH. Using a rigorous study design with data collection over 18 years in >5500 PWH, we found similarly high numbers (16.3% and 15.5%) of PWH with antibodies against *Leishmania infantum* in two consecutive cohorts. Moreover, PWH with antibodies against *Leishmania infantum* in Bahia, Brazil displayed a worse immune profile, with lower CD4 immune cells numbers and immune activation mediated by interferon, which we confirmed in independent HIV- and *Leishmania*-infected cohorts from other geographic areas. Our results underscore the need to raise awareness and define public health strategies to prevent HIV/*Leishmania* co-infection, since therapeutic failure and mortality are strongly increased in co-infected PWH, even with antiretroviral therapy as standard of care.

INTRODUCTION

HIV is the etiological agent of Acquired Immunodeficiency Syndrome (AIDS), a slowly progressive disease characterized by chronic immune activation resulting from the loss of cell-mediated immune function [1,2]. Host genetic factors (e. g. HLA genotypes) and host immune response (e.g. release of proinflammatory cytokines and chemokines), as well as the presence of co-infections, can directly influence the rate of disease progression [2–4].

Neglected Tropical Diseases (NTDs) are endemic among the most impoverished populations in Africa, Asia and Latin America. Among these NTDs, visceral leishmaniasis (VL), caused by infection with *Leishmania infantum*, is associated with increased morbidity and mortality in people with HIV-1 (PWH) but has not been recognized as a diagnostic criterion for AIDS [5]. The World Health Organization (WHO) identified the geographical overlap of both infections as an emerging challenge in successfully controlling the HIV-1 infection in countries considered endemic for leishmaniasis, such as Brazil [6].

The few studies evaluating the prevalence of HIV-1 and *L. infantum* coinfection on a national level in Brazil [7,8] have highlighted regions endemic for leishmaniasis: Distrito Federal [9], Ceará [10,11], Maranhão [12,13], Mato Grosso [14], Mato Grosso do Sul [15,16], Minas Gerais [17,18], Pernambuco [19], Piauí [20], Rio Grande do Norte [21,22], Sergipe [23] and Tocantins [24]. Bahia is also considered an endemic area for leishmaniasis, with an incidence rate of 0.08/10,000 inhabitants for VL reported in 2018 [25]. In addition, the increase of geographical overlap between HIV-1 and *Leishmania* infection in Bahia [25,26] has raised public health concerns. However, no

115 epidemiological studies have attempted to investigate the prevalence of co-infection to
116 date. Therefore, we investigated the seroprevalence of *L. infantum* in PWH in the state of
117 Bahia, Brazil and attempted to identify virological and immunological factors associated
118 with co-infection, supported by publicly available transcriptomic data.

METHODOLOGY

Study population and design

A two-stage cross-sectional cohort study (CSC-I, 1998-2013 and CSC-II, 2014-2015) was designed to determine the seroprevalence of *L. infantum* in PWH and to evaluate the association with demographic, clinical, virological and immunological parameters (Figure 1). From 1998 to 2015, individuals with a new confirmed diagnosis of HIV-1 at the Specialized Center for Diagnosis, Care and Research (CEDAP), a state government public health reference service located in the city of Salvador, Bahia-Brazil, were included in this study. Their remaining blood sample was utilized for the outlined assays herein. First, serological reactivity to *L. infantum* was assessed in plasma or serum samples from the retrospective cross-sectional cohort (n=5,346) collected between 1998 and 2013. In the second stage, serological reactivity to *L. infantum* was assessed in a prospective cross-sectional cohort of 317 PWH (sampled between July 2014 and December 2015), with demographic and clinical data (sex, age, HIV-1 viral load, CD4⁺, CD8⁺, CD4/CD8 ratio and CD45⁺ T cell counts) prospectively obtained from the clinical records. Additionally, we performed a subpopulation analysis on a subset of PWH identified as either double-positive or double-negative using two independent anti-*Leishmania* immunoassays. Based on these stringently defined categories, we compared virological and immunological factors influenced by *L. infantum* seropositivity. The study's recruitment did not interfere with standard medical care, and patients were treated according to the general Brazilian/WHO guidelines. This study was conducted following the Declaration of Helsinki and was approved by the Institutional Review Board of the Gonçalo Moniz Institute (IGM-FIOCRUZ) (protocol number 1.764.505).

Figure 1. Flow chart of study design detailing the two-stage cross-sectional and prospective cohort study among people living with HIV in Bahia, Brazil.

Detection of anti-*Leishmania* and anti-*Trypanosoma* antibodies

All samples underwent a previously described and validated in-house enzyme-linked immunosorbent assay (ELISA) for the detection of IgG against Soluble *Leishmania infantum* Antigen (SLA), which we previously demonstrated as a sensitive biomarker (90% sensitivity and 95% specificity) of current or past infection with the parasite [27]. SLA preparation and ELISA procedures were performed as previously described [28]. For the prospective cohort of 317 samples from PWH with digitalized clinical records, results of the SLA immunoassay were compared with a second, previously described ELISA employing recombinant *L. infantum* heat shock protein 70 (HSP70), for which we once found a sensitivity of 74% and a specificity of 73% [29]. To avoid false-positive results for *L. infantum* due to cross-reactivity among Trypanosomatidae parasites, an ELISA for anti-*Trypanosoma cruzi* IgG (Euroimmun) was employed in a subset of 42

samples with dual-positive (DP) (n=15) and double-negative (n=27) serology for anti-SLA and anti-HSP70.

Control samples and ELISA cutoff value

Positive (n=6) *Leishmania*-infected patient samples and negative (n=47) control samples previously identified by the intradermal Leishmanin (also known as Montenegro) Delayed-type Hypersensitivity (DTH) skin test, with clinical and laboratorial confirmation, were used to establish anti-SLA and anti-HSP70 ELISA cutoff values. For each assay, specific cutoff values were determined using the mean OD values obtained from the included negative samples plus three times the observed standard deviation, with each assay's index values corresponding to the OD/cutoff ratio (Supplementary Figure 1).

Quantification of immunological markers

A Cytometric Bead Array (CBA) Human Inflammatory Cytokines Kit (BD Biosciences) was employed to quantify plasma concentrations of IL-1 β , IL-6, IL-10, IL-12p70 and TNF, while CCL2/MPC-1, CCL5/RANTES, CXCL8/IL-8, CXCL9/MIG and CXCL10/IP-10 quantification was performed using a CBA Human Chemokine Kit (BD Biosciences), each following the manufacturer's instructions. Data acquisition and analysis were performed using a FACSArray Bioanalyzer (BD Biosciences) and FlowJo v.10.0.5 (Tree Star) software, respectively.

HIV-1 sequencing analyses

Viral RNA isolation was performed using a QIAamp Viral RNA Mini Kit (QIAGEN) following the manufacturer's instructions. The protease/reverse transcriptase (PR/RT) region was amplified and sequenced as previously described [30]. Outer polymerase

chain reaction (PCR) was performed using a SuperScript III One-Step RT-PCR System with Platinum Taq DNA Polymerase (Thermo Fisher Scientific) and the following primers: K1 (CAGAGCCAACAGCCCCACC) and K2 (TTTCCCCACTAACTTCTGTATGTCATTGACA) [31]. Inner PCR was performed using Platinum Taq DNA Polymerase High Fidelity (Thermo Fisher Scientific) with the following primers: DP16 (CCTCAAATCACTCTTTGGCAAC) and RT4 (AGTTCATAACCCATCCAAAG) [32]. The generated inner PCR products were sequenced using a BigDye Terminator v.3.1 Cycle Sequencing Kit (Applied Biosystems) with capillary electrophoresis run on an ABI 3500xL Genetic Analyzer (Applied Biosystems) employing the following primers: F1 (GTTGACTCAGATTGGTTGCAC), F2 (GTATGTCATTGACAGTCCAGC) [33], DP10 (CAACTCCCTCTCAGAAGCAGGAGCCG), DP11 (CCATTCCTGGCTTTAATTTTACTGGTA) [34], RT4 (AGTTCATAACCCATCCAAAG), GABO1 (CTCARGACTTYTGGGAAGTTC) and GABO2 (GCATCHCCCACATCYAGTACTG) [30]. Sequence visualization, editing and assembly were performed using Geneious v.10.0.8 (Biomatters) software. HIV-1 subtyping was determined using the REGA HIV-1 Subtyping Tool v.3.4.1 (<https://www.genomedetective.com/app/typingtool/hiv>) and the jpHMM-HIV approach [35]. Phylogenetic analysis was conducted using HIV-1 subtype references retrieved from the Los Alamos HIV sequence database (<https://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html>) (Supplementary Table 1). Phylogenetic inference was performed using PhyML v.3.0 [36], applying the BIONJ method and using the General Time Reversible (GTR) nucleotide substitution model with 1,000 bootstrap replicates.

Transcriptome and systems biology analysis

Transcriptome analysis of publicly available data was performed as recently described [37–39]. Overlap ratio was calculated as: $k/K = \# \text{ Genes in Overlap (k)} / \# \text{ Genes in Gene Set (K)}$ using Molecular Signatures Database (MSigDb). HIV-1 (Swiss HIV Cohort, n=137) [40] and *Leishmania*-infected individuals (Piaui Northeast Brazil Cohort, n=30) [41] were analyzed using GEO2R from Gene Expression Omnibus (GEO).

Statistical analysis

Since data were not normally distributed, as identified by the Shapiro-Wilk and D'Agostino-Pearson tests (GraphPad Prism v.7.0), results were analyzed using non-parametric tests: Mann-Whitney test and Spearman's correlation, as well as Fisher's exact test, with $p < 0.05$ considered statistically significant.

RESULTS

Detection of IgG antibodies against *Leishmania (L.) infantum* antigens (anti-SLA and anti-HSP70) in people living with HIV (PWH)

To determine the seroprevalence to *L. infantum* among PWHs, 5,346 plasma or serum samples from treatment-naïve HIV-1-infected individuals diagnosed between 1998 and 2013 were tested for the presence of IgG antibodies against soluble *L. infantum* antigen (anti-SLA) (Figure 1).

Positivity for anti-SLA serology was detected in 870/5,346 samples, resulting in an prevalence rate of 16.27% (Figure 2). Samples from patients with clinically confirmed diagnosis of visceral leishmaniasis (VL) and laboratory-confirmed *L. infantum* infection in the absence (n=16) or presence of HIV-1 co-infection (n=10) were used as an additional control [42]. As shown in Figure 2A, anti-SLA antibodies were detected in 81.25% and 100% of HIV-1-negative and HIV-1-positive VL patients, respectively. Besides, we found humoral immune response against SLA in VL patients quantitatively similar regardless of the presence of HIV-1 co-infection (Mann Whitney p=0.71, HIV-negative vs HIV-positive). Thus, we could confirm the high specificity of the *L. infantum* anti-SLA IgG serology protocol employed herein.

Figure 2. Detection of anti-*L. infantum* IgG antibodies in plasma/serum samples collected from PWH between 1998 and 2013. A) Violin plot with a dot-plot overlay of OD index values representative of *L. infantum* anti-SLA serology in the retrospective PWH cohort (n=5,346) and a clinical- and laboratory-confirmed control group (HIV-1⁻ VL⁺, n=16; and HIV-1⁺ VL⁺, n=10). Filled black circles (●): PWH cross-sectional cohort

samples; filled red circles (●): clinical HIV-1 negative controls with VL; filled red squares with black borders (■): clinical controls with HIV-1 positive controls and VL. B) Pie chart representation of samples (expressed as percentages) with positive (red) and negative (gray) anti-SLA *L. infantum* serology.

Subsequently, to validate our findings, we enrolled an independent prospective CSC between 2014 and 2015, composed of 317 treatment-naïve HIV-1-infected individuals from which complete demographic and clinical data were obtained from digitalized clinical records. Moreover, we combined anti-SLA serology with a second specific assay to detect IgG antibodies against *L. infantum* HSP70 recombinant protein (anti-HSP70) (Figure 1). The overall prevalence of anti-SLA positive serology in the prospective cohort was 15.46% (49/317), similar to the cross-sectional cohort results. The prevalence of anti-HSP70 positive serology in the prospective cohort was 8.20% (26/317) (Figure 3). Positivity for both anti-SLA and anti-HSP70 (i.e., double-positivity – DP) was detected in 4.73% (15/317) of the cohort; anti-SLA positive serology alone was detected in 10.73% (34/317); anti-HSP70 serology alone in only 3.47% (11/317) and the union of both anti-SLA and anti HSP70 positive serology was detected in 18.93% (Figure 3D).

Figure 3. Detection of anti-*L. infantum* IgG antibodies in plasma samples collected from PWH between 2014 and 2015. A) Violin plot with a dot-plot overlay of OD index values representative of *L. infantum* anti-SLA and anti-HSP70 serology in the PWH prospective cohort (n=317). The red symbols represent the DP individual diagnosed with visceral leishmaniasis >20 years ago. B-C) Pie chart representation (expressed as percentages) of samples positive for B) *L. infantum* anti-HSP70 (blue) and C) *L. infantum* anti-SLA (red). Percentages of negative samples are depicted in gray. D) Venn diagram illustrating overlap in detection between *L. infantum* anti-SLA and anti-HSP70 serological methods.

Based on these findings, DP (n=15) was adopted as the most stringent criterium for *L. infantum* infection. Assessment of standard diagnosis of previous or ongoing visceral leishmaniasis (VL) documented in the clinical records showed that one of the 15 DP

subjects had VL reported >20 years ago (anti-SLA index=4.71; anti-HSP70 index=2.67). After two decades of clinical diagnosis, this pronounced humoral response most likely reflects chronic antigen exposure, supporting the concept that *Leishmania* infection is lifelong in most patients as observed in murine models of disease [43–45]. These results, taken together, demonstrated that a significant number of PWH in the state of Bahia are unaware of their exposure to and/or infection by *L. infantum* and are at risk of developing new or relapsing visceral leishmaniasis.

Demographic and clinical markers associated with dual-positive *L. infantum* serology in PWH

The CSC-II (n=317) consisted of predominantly young males (72.23%) with a median age of 32 years old at the time of HIV diagnosis, median viral load of 40,370 copies/mL (IQR=7,032-141,359), CD4⁺ T cell count of 369 cells/ μ L (IQR=163-609), CD8⁺ T cell count of 1,025 cells/ μ L (IQR=715-1,441), and CD45⁺ T cell count of 2,144 cells/ μ L (IQR=1,507-2,763) (Table 1).

Table 1. Epidemiological, virological and immunological characteristics of PWH in Bahia (Brazil) between 2014 and 2105, stratified according to DP and DN_{total}. Data are expressed as median values, interquartile ranges (IIQ) and numbers of individuals evaluated (N), or as proportions (%) with the number of individuals evaluated in parentheses. The Mann-Whitney test was used to determine statistical differences between DP and DN_{total}; *p* values considered statistically significant (*p*<0.05) are shown in bold. DP: dual-positive; DN_{total}: total double-negative; NA: not analyzed

	n=317	DP (n=15)	DN _{total} (n=257)	<i>p</i> value
Male, n	72.23% (229)	73.33% (11)	70.42% (181)	NA

Age, years	32 (26-41)	41 (30-50)	32 (25-39)	0.0430
HIV-1 viral load, copies/mL	40,370 (7,032-141,359)	64,746 (2,480-532,702)	34,956 (6,330-127,747)	0.1268
CD4 ⁺ T cell count, cell/ μ L	369 (163-609)	168 (107-449)	405 (188-641)	0.0208
CD8 ⁺ T cell count, cell/ μ L	1,025 (715-1,441)	950 (688-1,546)	1025 (728-1,443)	0.8679
CD4 ⁺ /CD8 ⁺ T cell ratio	0.33 (0.14-0.59)	0.21 (0.060-0.37)	0.35 (0.15-0.63)	0.0282
CD45 ⁺ T cell count, cell/ μ L	2,144 (1,507-2,763)	1,758 (1,142-3,028)	2,198 (1,585-2,793)	0.3262

Comparative analyses between the DP (n=15) and total double-negative (DN_{total}) (n=257) groups indicated that individuals with antibodies against both SLA and HSP70 *L. infantum* were older (p=0.0430), presented lower baseline CD4⁺ T cell counts (p=0.0208) and lower CD4⁺/CD8⁺ T cell ratios (p=0.0282), as well as a tendency towards higher HIV-1 viral load levels (p=0.1268) suggestive of an advanced stage of HIV-1 infection than individuals without *L. infantum* antibodies (Table 1). Indeed, a large proportion of DP individuals (10/15, 66.67%) had <200 CD4⁺ T cells/ μ L at the time of HIV-1 diagnosis, which is considered AIDS-defining.

Subpopulation analysis reveals virological and immunological markers associated with dual-positive *L. infantum* serology in PWH

To ensure specificity for *L. infantum* in the DP serological samples and to exclude the possibility of cross-reactivity due to polyclonal activation and hypergammaglobulinemia, anti-*Trypanosoma cruzi* IgG serology was performed. Samples demonstrating positivity for anti-*T. cruzi* IgG (n=2) were excluded from subsequent analyses (Supplementary Figure 2). Next, we performed a subpopulation analysis by matching DN individuals to the DP group by gender, age, viral load and CD4⁺ T cell count. This strategy resulted in the establishment of a third group (DN_{paired}) (Figure 1), thereby mitigating the possibility of bias arising from polyclonal activation, hypergammaglobulinemia, high viral load or low CD4⁺ T cell levels. Controlling for these parameters limited the potential for

variations in the HIV-1 transcriptomic profile and the state of immune activation. No statistical differences were observed between the DP and DN_{paired} groups regarding sociodemographic and clinical parameters, which underscores the pairing strategy's equity (Table 2).

Table 2. Epidemiological, virological and immunological characteristics of PWH in Bahia (Brazil) between 2014 and 2105, stratified according to DP and DN_{paired}.

Data are expressed as median values, interquartile ranges (IIQ) and numbers of individuals evaluated (N), or as proportions (%) with the number of individuals evaluated in parentheses. The Mann-Whitney test was used to determine statistical differences between DP and DN_{paired}; *p* values considered statistically significant (*p*<0.05) are shown in bold. DP: dual-positive; DN_{paired}: total double-negative; NA: not analyzed

	DP (n=14)	DN _{paired} (n=26)	<i>p</i> value
Male, n	78.57% (11)	88.46% (23)	NA
Age, years	42 (29-51)	33 (26-43)	0.2224
HIV-1 viral load, copies/ml	147,580 (2,284-700,074)	76,298 (15,757-141,159)	0.4572
CD4+ T cell count, cell/μl	166 (91-450)	300 (128-472)	0.4113
CD8+ T cell count, cell/μl	1,008 (744-1,607)	995 (852-1,489)	0.7474
CD4+/CD8+ T cell ratio	0.21 (0.058-0.39)	0.29 (0.14-0.49)	0.3954
CD45+ T cell count, cell/μl	1,788 (1,262-3,054)	1,958 (1,628-2,585)	0.6641

To investigate possible associations between transmission clusters of a more-aggressive HIV subtype and worsen HIV clinical status, HIV-1 subtyping was performed in the DP and DN_{paired} subset to infer. After excluding samples with a viral load <1,000 copies/mL, both groups were pooled together (n=19) and submitted to phylogenetic analysis using the jpHMM-HIV model (Supplementary Figure 3). Concerning subtype distribution,

subtype B (63.16%, 12/19) was the most prevalent, followed by subtypes C (15.79%, 3/19), recombinant BF (15.79%, 3/19) and D (5.26%, 1/19). No statistical differences in subtype were observed between the DP and DN_{paired} groups (p=0.67) (Supplementary Table 2). No transmission cluster was identified. HIV-1 subtyping showed no impact on *L. infantum* serology titers, viral load, T cell count, or any other host immunological marker evaluated, indicating that HIV-1 subtypes B, C, D, F1 and BF exhibit similar virological and immunological outcome in HIV/*L. infantum* co-infection.

Next, we quantified circulating cytokines and chemokines that might reflect an increase in systemic immune activation and have been previously associated with infection to *L. infantum* [46–49]. The systemic levels of cytokines tested (IL-1 β , IL-6, IL-10, IL-12p70 and TNF) were below the detection limits in all samples (DP and DN_{paired} groups), concordant with our previous findings in a large Cuban cohort of PWH [4]. Conversely, most chemokines (except IL-8) were readily detected in most PWH, demonstrating a significant increase in CXCL10/IP-10 (p=0.0076) and a tendency towards higher CXCL9/MIG levels (p=0.061) (Figure 4) in the DP group compared to DN_{paired}, suggesting increased immune activation in the group with DP serology for *L. infantum*.

Figure 4. Chemokine profiles obtained from plasma/serum samples of DP and DN_{paired} groups. A-E) Violin plots with dot-plot overlays illustrating chemokine plasma levels (pg/mL). Statistical comparisons made by the Mann-Whitney test in plasma levels (pg/mL) of CCL2/MPC-1 (p=0.43), CCL5/RANTES (p=0.94), CXCL8/IL-8 (p=0.54), CXCL9/MIG (p=0.061) and CXCL10/IP-10 (p=0.0076) chemokines. Open squares (□): subgroup of double-positive PWH (positive for both anti-SLA and anti-HSP70 *L. infantum* antigens); open circle (○): subgroup of paired double-negative PWH (serologically negative for anti-SLA and anti-HSP70 *L. infantum* antigens). The red

symbol represents the DP individual diagnosed with visceral leishmaniasis >20 years ago.

F) Heat map shows the correlation (pink: positive correlation; blue: negative correlation; white: no correlation) of epidemiological, virological and immunological characteristics of PWH.

This finding, together with the decreased CD4⁺ T cell counts found in our previous analysis (Table 2), corroborates the hypothesis that therapy-naïve HIV-1-infected subjects previously or currently infected with *L. infantum* exhibit a more intensified state of immune activation than HIV-1 positive, *L. infantum* seronegative subjects. During clinical follow-up, the introduction of antiretroviral therapy restored CD4⁺ T cell counts (median values of CD4⁺ T cell counts after 4-5 years of follow-up: DP=620 cells/μL and DN_{paired}=870 cells/μL) and reduced viral load levels to undetectable limits similarly in each group (Figure 5), with no statistically significant differences between groups (AUC comparison, data not shown).

Figure 5. Long-term follow-up of CD4⁺, CD8⁺, CD4/CD8 ratio, CD45⁺ and viral load levels after therapy introduction in DP and DN_{paired} groups. A-J) Box plots with line plot overlays connecting medians of CD4⁺, CD8⁺, CD4/CD8 ratio, CD45⁺ and viral load levels during follow-up. A and F) Follow-up of viral load (copies/mL) in DN_{paired} (A) and DP (F) groups. B and G) Follow-up of CD4⁺ T cell count (cells/ μ L) in DN_{paired} (B) and DP (G) groups. C and H) Follow-up of CD8⁺ T cell count (cells/ μ L) in DN_{paired} (C) and DP (H) groups. D and I) Follow-up of CD4/CD8 (ratio) in DN_{paired} (D) and DP (I) groups. E and J) Follow-up of CD45⁺ T cell count (cells/ μ L) in DN_{paired} (E) and DP (J) groups.

***CXCL10* is shared between the HIV and visceral leishmaniasis gene signatures, while *CXCL10*, *CXCL9* and *CCL2* positively correlate with HIV viral load in untreated PWH**

Given the small number of immune activation markers and modest cohort size for the paired DP and DN groups, we aimed to validate and extend our findings by cross-examining independent cohorts of HIV-1 (Swiss HIV Cohort, n=137) or *Leishmania*-infected individuals with and without active disease (Piauí Northeast Brazil, n=30) with publicly available transcriptome-wide data [40,41]. As shown in Figure 6A-B, a significant overlap (41 genes, enrichment $p < 0.0001$) was found between the HIV and visceral leishmaniasis gene signatures when comparing the top 500 transcripts significantly upregulated during active disease in both untreated HIV patients and untreated visceral leishmaniasis patients, as compared to their paired post-treatment groups. A systems biology analysis of the 41 genes shared by HIV and leishmaniasis active disease signatures revealed several significantly enriched biological processes, encompassing immune activation broadly and, more specifically, type I IFN signaling and antiviral response. The overlapping genes included *CXCL10*, which we found to be

overexpressed in the DP group of our prospective cohort, as well as *STAT1*, the major transcription factor activated by IFN signaling. As detailed in Figure 6A and Supplementary Tables 3-5, enriched gene sets from Molecular Signatures Database (MSigDb) representing 'immune activation' included graft-versus-host disease, antigen recognition and blister cytotoxicity, while enriched gene sets representing 'type I IFN/antiviral response' comprised those upregulated in the liver by HBV infection, by IFN-alpha treatment of fibroblasts *in vitro* and by IFN-beta treatment of multiple sclerosis patients *in vivo*. Of interest, *IFNG* transcripts significantly decrease in monoinfected visceral leishmaniasis individuals, confirming our previous results obtained at the protein level for systemic IFN- γ in two independent VL cohorts [46,49].

Figure 6. CXCL10 is shared between the HIV and visceral leishmaniasis disease signatures while CXCL10, CXCL9 and CCL2 transcripts positively correlate with HIV viral load in untreated PWH. Venn diagrams show overlap between (A) active disease gene signatures, i.e. genes upregulated in untreated PWH (Swiss cohorts) and visceral leishmaniasis patients (as compared to post-treatment) and (B) genes upregulated

in untreated PWH and asymptomatic *Leishmania*-infected individuals (who did not develop disease). Systems biology analysis shows a significant enrichment of gene sets comprising immune activation and type I IFN signaling (right-hand panels). (C) Selective up-regulation of *CXCL10* and *STAT1* (as a positive control for IFN signaling) transcripts in both untreated visceral leishmaniasis patients (upper panel) and *Leishmania infantum*-exposed individuals (D) Selective up-regulation (upper panel) and positive correlation to viral load (lower panel) of *CXCL10*, *CXCL9* and *CCL2* and *STAT1* (as a positive control for IFN signaling) transcripts in untreated PWH (Swiss cohort, n=137).

To define a specific '*Leishmania* infection' gene signature, we used the top 500 significantly upregulated transcripts from *Leishmania*-infected individuals who did not develop disease, for which *Leishmania* infection was documented by a positive skin DTH reaction, as compared to matched DTH-negative individuals from the same endemic area [41]. Surprisingly, the overlap between the 'untreated HIV' and '*Leishmania*-seropositive (DP)' gene signatures was even more pronounced than the overlap between the 'untreated HIV' and 'untreated visceral leishmaniasis' gene signatures, both by quantitative (65 shared genes, Figure 6B) and qualitative measures (median gene set overlap 9.4% vs 3.2%, Mann-Whitney $p < 0.0001$, Supplementary Table 3), indicating that even asymptomatic *Leishmania* infection has a profound effect on the systemic immune response. Again, *CXCL10* and *STAT1* were shared among the two disease signatures (Figure 6B), and enriched gene sets included type I IFN signaling (genes upregulated by IFN-beta treatment of multiple sclerosis patients *in vivo* and by IFN-alpha treatment of fibroblasts *in vitro*) and immune activation (inflammatory response to LPS, TNF signaling).

450 Validation of our DP cohort results revealed that *CXCL10*, but not *CCL2*, *CCL5* or
 451 *CXCL8* transcripts, were significantly upregulated by *Leishmania infantum* infection with
 452 or without clinically definite visceral leishmaniasis (Figure 6C upper and lower panel).
 453 In the Swiss HIV Cohort, we found that *CXCL10*, *CCL2* and, to a lesser extent, *CXCL9*
 454 transcripts were significantly upregulated during untreated HIV-1 infection. In contrast,
 455 no significant effect was observed for *CXCL8* in either asymptomatic or symptomatic
 456 *Leishmania infantum* infection, supporting our negative findings for *CXCL8* genetic
 457 variation in visceral leishmaniasis patients from the same endemic region [47]. However,
 458 *CXCL8* transcripts were significantly downregulated during untreated HIV-1 infection
 459 (Figure 6D upper panel). Finally, as shown in Figure 6D (lower panel), *CCL2*, *CXCL9*
 460 and *CXCL10* transcripts were significantly correlated (even after stringent correction for
 461 genome-wide testing) with set point viral load in untreated PWH from the Swiss HIV
 462 Cohort (n=137), confirming the results from our prospective cross-sectional cohort
 463 (Figure 4F).

DISCUSSION

The geographic overlap of HIV-1 and *L. infantum* infections raises the possibility of co-infection, which several groups have shown to increase morbidity and mortality [7,11,52–58,13,14,19,21–23,50,51]. Several groups have studied the extent of this overlap in several Brazilian regions. However, no studies have attempted to determine the seroprevalence of *L. infantum* among PWH in the state of Bahia, despite the significant prevalence of both infections [25,26]. We used a two-stage cross-sectional cohort approach (CSC-I, n=5,346 and CSC-II, n=317) and identified positive serology for *L. infantum* ranging from 4.73% (DP for anti-SLA and anti-HSP70) to 18.93% in the CSC-II (union of all positive samples for anti-SLA and anti-HSP70), with an intermediate seroprevalence for only anti-SLA of 16.27% in the CSC-I and 15.46% in the CSC-II. The observed frequencies of *Leishmania* seroprevalence in PWH using any of the serology strategies in both the cross-sectional cohorts support previous findings falling within the range of what has already been described in other Brazilian regions [9,12,20,59]. Moreover, demographic data indicated that all DP patients were born in the macoregions surrounding the cities of Salvador and Feira de Santana, which are responsible for 33.8% (1,074/3,172) of notified VL cases in Bahia between 2007 and 2015 [25].

The observed discrepancy between the results obtained with the two different immunoassays might be explained by the rigor employed to determine cutoffs for each serological test and the imbalance in protein fractions between these two antigen-based diagnostic methods. SLA is a heterogeneous mix of antigens and has a lower concentration of HSP70 than parasite structural proteins (actin, tubulin, etc.). Even though it will pick up a broader set of samples, some samples with low antibody levels will fail. On the other hand, the recombinant HSP70 antigen is homogenous and highly

concentrated and has a better detection limit. We considered only those samples demonstrating dual positivity to increase confidence regarding past or present *L. infantum* infection. This strategy was underscored by the identification of one individual with a previous history of VL in the DP group and no cases with an earlier history of VL in the DN_{paired} group.

Unfortunately, only serum or plasma samples were available for HIV-1 RNA extraction, thus precluding DNA analysis to detect *L. infantum* by qPCR, which we acknowledge as a limitation of our study. However, Fukutani *et al.* (2014) [60] demonstrated a concordance of 68% between anti-SLA serology and PCR, and found a 5.40% rate of ongoing asymptomatic *L. infantum* infection among blood donors in Salvador, Bahia. Nevertheless, positive IgG serology for *L. infantum* indicates immunological memory of at least a previous *Leishmania* infection before HIV diagnosis. Strikingly, we identified a DP individual with a pronounced humoral response two decades after a VL clinical diagnosis. This ongoing humoral response most likely reflects chronic antigen exposure, emphasizing the concept that *Leishmania* infection is lifelong in most patients, as well as murine models of disease [43–45]. A wealth of studies worldwide [14,42,61–64] and a recent systematic review [56] have demonstrated a high frequency of relapse of VL in PWH, as well as increased mortality. Relapse of VL have been reported after anti-leishmaniasis treatment, even years after the patient was considered clinically cured, especially in PWH and/or immunosuppressive conditions [13,51].

Prior large studies, including from our group, have found striking differences in the prevalence of VL within different regions in Brazil, as well as Southern Europe. The highest seroprevalence was observed in Mato Grosso, 41.40% of blood donors, in contrast

to other regions in Brazil (Salvador: 5.40% of 700 [60]; Paraná: 11.40% of 176 [65]; Fortaleza: 17.10% of 431 [66]), and in Southern Europe (France: 13.40% of 565 [67]; Spain: 3.10% of 1,437 [68]).

Studies conducted in populations of newly diagnosed HIV-1-infected individuals from regions endemic for leishmaniasis in Brazil reported a prevalence of HIV-1/*L. infantum* co-infection ranging from 4.20% to 20.20%. In these studies, *L. infantum* infection was determined by parasitological, serological and/or molecular testing [9,12,20,59]. However, in co-infection studies focused on VL patients, which were diagnosed by parasitological, molecular or immunofluorescence methods, the prevalence of HIV-1/*L. infantum* coinfection ranged from 36.60% to 55.60% [16–18].

The present study also investigated possible differences in the prevalence of HIV-1 variants associated with *L. infantum* infection in PWH. With these subtyping results, we would like to investigate if a possible worsen disease progression in PWH with positive serology for *L. infantum* cases was related to cluster of transmission of a more-aggressive HIV subtype (e.g. HIV Subtype D) [69]. However, no differences were found concerning HIV-1 isolates between matched samples of patients infected (DP) or not (DN_{paired}) to *L. infantum*. Within these isolates, subtype B (63.16%) was found to be the most prevalent, followed by C (15.79%), recombinant BF (15.79%) and D (5.26%). Recent studies in Bahia that evaluated HIV-1 variant distribution have described the wide distribution of subtype B, followed by a smaller proportion of recombinant BF units [70–72]. Of note, the higher prevalence of subtype C (15.79%) found herein stands in contrast to other studies also conducted in this region, which reported a very low prevalence ranging from 1.70% to 2.50% [71,73,74].

539

540 Moreover, our confirmation of the circulation of subtype D in the state is following work
541 by Monteiro *et al.* (2009) [75], who previously reported the presence of subtype D in
542 individuals from Feira de Santana (0.60% of polF/envD subtype), a city located ~100 km
543 from Salvador. It is worth noting that the subtyping analysis performed herein involved
544 three different methodologies (REGA HIV-1 Subtyping Tool, phylogeny and jpHMM-
545 HIV probabilistic modeling), which lends support to the presently reported distribution.
546 Furthermore, our subtype identification was performed using HIV-1 *pol* sequences,
547 inferring subtype frequencies can vary when complete genome sequencing is performed.
548

549 Prior research into host immune responses has demonstrated that *L. infantum* infection
550 induces a higher level of immune activation in co-infected PWH, which could lead to a
551 more rapid progression to AIDS [3,76–78]. Our study found a roughly five-fold increase
552 in circulating CXCL10/IP-10 and CXCL9/MIG chemokines in PWH exposed to *L.*
553 *infantum*, supporting a link between positive serology for *L. infantum* and immune
554 activation, which we validated at the transcript level for CXCL10 in independent HIV-1
555 and *Leishmania*-infected cohorts. These chemokines are strongly induced by both type I
556 (IFN- α/β) and type II IFN (IFN- γ) [79–82]. It has been previously reported that Th1
557 subpopulations of CD4⁺CD95⁺ T cells in HIV-1 infected individuals are highly
558 susceptible to HIV-1 envelope gp120-induced apoptosis [83,84], which may corroborate
559 the deleterious role of intensified immune activation [85–87]. In a submitted manuscript
560 (Khouri *et al.*), we demonstrated an increase in both systemic soluble Fas as well as
561 membrane-bound Fas/CD95 expression in CD8⁺ cells in HIV/VL co-infection, as
562 compared to HIV-1 or VL mono-infected groups, in a large cohort of individuals recruited
563 during an outbreak of VL in Piauí, another state in the same northeast region of Brazil.

Since we previously demonstrated STAT1-mediated IFN signaling as a preferential inducer of Fas/CD95 at both the protein and transcript level [88,89], this study as well as Khouri *et al.* (submitted) underscore the pivotal role of IFN-driven immune activation in HIV-1 and *Leishmania infantum* co-infection and its deleterious effect on both AIDS progression and visceral leishmaniasis.

The present study aimed to describe the prevalence and consequences of *L. infantum* infection in a population of antiretroviral treatment-naïve PWH at diagnosis. We found a high seroprevalence of *L. infantum* in treatment-naïve PWH in Bahia (Brazil) associated with a more intensified state of immune activation as compared to HIV-1 monoinfected subjects, possibly exacerbating progression to AIDS, which was observed in 66.67% in co-infected individuals at diagnosis. Moreover, *Leishmania*-infected PWH are at high risk of developing severe visceral leishmaniasis [56]. These findings underscore the urgent need to increase awareness and define public health strategies for the management and prevention of HIV-1 and *L. infantum* co-infection.

579 **FUNDING**

580 This work was financed in part by Fundação de Amparo à Pesquisa do Estado da Bahia
 581 (FAPESB, APP0032/2016), Coordenação de Aperfeiçoamento de Pessoal de Nível
 582 Superior (CAPES – finance code 001) and FWO (grant G0D6817N). None of the funding
 583 organizations had any role in the study design, data collection, data interpretation or
 584 writing of this report.

585

586 **ACKNOWLEDGMENTS**

587 The authors would like to thank Andris K. Walter for English language revision and
 588 manuscript copyediting assistance.

REFERENCES

1. Costin JM. Cytopathic Mechanisms of HIV-1. *Virology*. 2007;4: 100. doi:10.1186/1743-422X-4-100
2. Perkins MR, Bartha I, Timmer JK, Liebner JC, Wollinsky D, Günthard HF, et al. The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. *J Infect Dis*. 2015;212: 578–584. doi:10.1093/infdis/jiv089
3. Claiborne DT, Prince JL, Scully E, Macharia G, Micci L, Lawson B, et al. Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4 + T cells, and disease progression. *Proc Natl Acad Sci*. 2015;112: E1480–E1489. doi:10.1073/pnas.1421607112
4. Kouri V, Khouri R, Alemán Y, Abrahantes Y, Vercauteren J, Pineda-Peña A-C, et al. CRF19_cpx is an Evolutionary fit HIV-1 Variant Strongly Associated With Rapid Progression to AIDS in Cuba. *EBioMedicine*. 2015;2: 244–254. doi:10.1016/j.ebiom.2015.01.015
5. van Griensven J, Ritmeijer K, Lynen L, Diro E. Visceral Leishmaniasis as an AIDS Defining Condition: Towards Consistency across WHO Guidelines. Ghedin E, editor. *PLoS Negl Trop Dis*. 2014;8: e2916. doi:10.1371/journal.pntd.0002916
6. World Health Organization. Investing To Overcome the Global Impact of Neglected Tropical Diseases: third WHO Report on Neglected Tropical Diseases. 2015.
7. Coura-Vital W, Araújo VEM de, Reis IA, Amancio FF, Reis AB, Carneiro M. Prognostic Factors and Scoring System for Death from Visceral Leishmaniasis: An Historical Cohort Study in Brazil. Santiago H da C, editor. *PLoS Negl Trop Dis*. 2014;8: e3374. doi:10.1371/journal.pntd.0003374

- 614 8. Leite de Sousa-Gomes M, Nilce Silveira Maia-Elkhoury A, Maria Pelissari D,
615 Edilson Ferreira de Lima Junior F, Martins de Sena J, Paula Cechinel M.
616 Coinfecção Leishmania-HIV no Brasil: aspectos epidemiológicos, clínicos e
617 laboratoriais. Epidemiol e Serviços Saúde. 2011;20: 519–526. doi:10.5123/S1679-
618 49742011000400011
- 619 9. Carranza-Tamayo CO, Assis TSM de, Neri ATB, Cupolillo E, Rabello A, Romero
620 GAS. Prevalence of Leishmania infection in adult HIV/AIDS patients treated in a
621 tertiary-level care center in Brasília, Federal District, Brazil. Trans R Soc Trop
622 Med Hyg. 2009;103: 743–748. doi:10.1016/j.trstmh.2009.01.014
- 623 10. Távora LGF, Nogueira MB, Gomes ST. Visceral Leishmaniasis/HIV co-infection
624 in northeast Brazil: evaluation of outcome. Brazilian J Infect Dis. 2015;19: 651–
625 656. doi:10.1016/j.bjid.2015.07.004
- 626 11. Diniz LFB, de Souza CDF, do Carmo RF. Epidemiology of human visceral
627 leishmaniasis in the urban centers of the lower-middle São Francisco Valley,
628 Brazilian semiarid region. Rev Soc Bras Med Trop. 2018;51: 461–466.
629 doi:10.1590/0037-8682-0074-2018
- 630 12. Carvalho FL, Aires DLS, Segunda ZF, Azevedo CMPES De, Corrêa RDGCF,
631 Aquino DMC de, et al. Perfil epidemiológico dos indivíduos HIV positivo e
632 coinfecção HIV-Leishmania em um serviço de referência em São Luís, MA, Brasil.
633 Cien Saude Colet. 2013;18: 1305–1312. doi:10.1590/S1413-81232013000500015
- 634 13. Silva de Lima UR, Vanolli L, Moraes EC, Ithamar JS, Pedrozo e Silva de Azevedo
635 C de M. Visceral leishmaniasis in Northeast Brazil: What is the impact of HIV on
636 this protozoan infection? PLoS One. 2019;14: 1–14.
637 doi:10.1371/journal.pone.0225875
- 638 14. Luz JGG, Naves DB, de Carvalho AG, Meira GA, Dias JVL, Fontes CJF. Visceral

leishmaniasis in a Brazilian endemic area: An overview of occurrence, HIV coinfection and lethality. *Rev Inst Med Trop Sao Paulo*. 2018;60: 1–9. doi:10.1590/S1678-9946201860012

15. Botelho ACA, Natal D. Primeira descrição epidemiológica da leishmaniose visceral em Campo Grande, Estado de Mato Grosso do Sul. *Rev Soc Bras Med Trop*. 2009;42: 503–508. doi:10.1590/S0037-86822009000500006

16. Druzian AF, Souza AS de, Campos DN de, Croda J, Higa MG, Dorval MEC, et al. Risk Factors for Death from Visceral Leishmaniasis in an Urban Area of Brazil. *PLoS Negl Trop Dis*. 2015;9: e0003982. doi:10.1371/journal.pntd.0003982

17. Cota GF, de Sousa MR, de Mendonça ALP, Patrocinio A, Assunção LS, de Faria SR, et al. Leishmania-HIV Co-infection: Clinical Presentation and Outcomes in an Urban Area in Brazil. Debrabant A, editor. *PLoS Negl Trop Dis*. 2014;8: e2816. doi:10.1371/journal.pntd.0002816

18. Souza GF de, Biscione F, Greco DB, Rabello A. Slow clinical improvement after treatment initiation in Leishmania/HIV coinfecting patients. *Rev Soc Bras Med Trop*. 2012;45: 147–150. doi:10.1590/S0037-86822012000200001

19. Sousa JM dos S, Ramalho WM, De Melo MA. Demographic and clinical characterization of human visceral leishmaniasis in the State of Pernambuco, Brazil between 2006 and 2015. *Rev Soc Bras Med Trop*. 2018;51: 622–630. doi:10.1590/0037-8682-0047-2018

20. Soares VYR, Lúcio Filho CEP, Carvalho LIM de, Silva AMM de M e, Eulálio KD. Clinical and epidemiological analysis of patients with HIV/AIDS admitted to a reference hospital in the northeast region of Brazil. *Rev Inst Med Trop Sao Paulo*. 2008;50: 327–332. doi:10.1590/S0036-46652008000600003

21. Lima ÁLM, de Lima ID, Coutinho JFV, de Sousa ÚPST, Rodrigues MAG, Wilson

ME, et al. Changing epidemiology of visceral leishmaniasis in northeastern Brazil: A 25-year follow-up of an urban outbreak. *Trans R Soc Trop Med Hyg.* 2017;111: 440–447. doi:10.1093/trstmh/trx080

22. Lima ID, Lima ALM, Mendes-Aguiar C de O, Coutinho JFV, Wilson ME, Pearson RD, et al. Changing demographics of visceral leishmaniasis in northeast Brazil: Lessons for the future. *PLoS Negl Trop Dis.* 2018;12: 1–16. doi:10.1371/journal.pntd.0006164

23. Santos GDO, De Jesus NPS, Cerqueira-Braz JV, Santos VS, De Lemos LMD. Prevalence of HIV and associated factors among visceral leishmaniasis cases in an endemic area of Northeast Brazil. *Rev Soc Bras Med Trop.* 2019;52: 1–4. doi:10.1590/0037-8682-0257-2018

24. Albuquerque LCP de, Mendonça IR, Cardoso PN, Baldaçara LR, Borges MRMM, Borges J da C, et al. HIV/AIDS-related visceral leishmaniasis: a clinical and epidemiological description of visceral leishmaniasis in northern Brazil. *Rev Soc Bras Med Trop.* 2014;47: 38–46. doi:10.1590/0037-8682-0180-2013

25. Secretaria de Saúde do Estado da Bahia. Informe Epidemiológico de Leishmaniose Visceral, Bahia. 2018.

26. Secretaria Municipal de Saúde de Salvador. Boletim Epidemiológico de AIDS: Situação Epidemiológica da AIDS em Salvador, Bahia. 2019.

27. Charlab R, Barral-Netto M, Valenzuela JG, Barral A, Caldas A, Honda E, et al. Human immune response to sand fly salivary gland antigens: a useful epidemiological marker? *Am J Trop Med Hyg.* 2000;62: 740–745. doi:10.4269/ajtmh.2000.62.740

28. Souza AP, Soto M, Costa JML, Boaventura VS, de Oliveira CI, Cristal JR, et al. Towards a More Precise Serological Diagnosis of Human Tegumentary

Leishmaniasis Using Leishmania Recombinant Proteins. Zamboni DS, editor. PLoS One. 2013;8: e66110. doi:10.1371/journal.pone.0066110

29. Soto M, Corvo L, Garde E, Ramírez L, Iniesta V, Bonay P, et al. Coadministration of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice. Melby PC, editor. PLoS Negl Trop Dis. 2015;9: e0003751. doi:10.1371/journal.pntd.0003751

30. Barreto CC, Nishyia A, Araújo L V., Ferreira JE, Busch MP, Sabino EC. Trends in antiretroviral drug resistance and clade distributions among HIV-1-infected blood donors in Sao Paulo, Brazil. J Acquir Immune Defic Syndr. 2006;41: 338–341. doi:10.1097/01.qai.0000199097.88344.50

31. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med. 1996;2: 753–759. doi:10.1038/nm0796-753

32. Pieniazek D, Peralta JM, Ferreira JA, Krebs JW, Owen SM, Sion FS, et al. Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction. AIDS. 1991;5: 1293–1300. doi:10.1097/00002030-199111000-00002

33. Frenkel LM, Wagner LE, Atwood SM, Cummins TJ, Dewhurst S. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J Clin Microbiol. 1995;33: 342–347. doi:10.1128/jcm.33.2.342-347.1995

34. Janini LM, Pieniazek D, Peralta JM, Schechter M, Tanuri A, Vicente ACP, et al. Identification of single and dual infections with distinct subtypes of human immunodeficiency virus type 1 by using restriction fragment length polymorphism analysis. Virus Genes. 1996;13: 69–81. doi:10.1007/BF00576981

- 714 35. Schultz A-K, Zhang M, Bulla I, Leitner T, Korber B, Morgenstern B, et al.
715 jpHMM: Improving the reliability of recombination prediction in HIV-1. *Nucleic*
716 *Acids Res.* 2009;37: W647–W651. doi:10.1093/nar/gkp371
- 717 36. Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New
718 Algorithms and Methods to Estimate Maximum-Likelihood Phylogenies:
719 Assessing the Performance of PhyML 3.0. *Syst Biol.* 2010;59: 307–321.
720 doi:10.1093/sysbio/syq010
- 721 37. Vivarini áislan de C, Calegari-Silva TC, Saliba AM, Boaventura VS, França-Costa
722 J, Khouri R, et al. Systems Approach Reveals Nuclear Factor Erythroid 2-Related
723 Factor 2/Protein Kinase R Crosstalk in Human Cutaneous Leishmaniasis. *Front*
724 *Immunol.* 2017;8: 1–18. doi:10.3389/fimmu.2017.01127
- 725 38. Subramanian K, Dierckx T, Khouri R, Menezes SM, Kagdi H, Taylor GP, et al.
726 Decreased RORC expression and downstream signaling in HTLV-1-associated
727 adult T-cell lymphoma/leukemia uncovers an antiproliferative IL17 link: A
728 potential target for immunotherapy? *Int J Cancer.* 2019;144: 1664–1675.
729 doi:10.1002/ijc.31922
- 730 39. Delgobo M, Mendes DAGB, Kozlova E, Rocha EL, Rodrigues-Luiz GF, Mascarin
731 L, et al. An evolutionary recent IFN/IL-6/CEBP axis is linked to monocyte
732 expansion and tuberculosis severity in humans. *Elife.* 2019;8: 1–32.
733 doi:10.7554/eLife.47013
- 734 40. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, et al. Genome-
735 Wide mRNA Expression Correlates of Viral Control in CD4+ T-Cells from HIV-
736 1-Infected Individuals. Emerman M, editor. *PLoS Pathog.* 2010;6: e1000781.
737 doi:10.1371/journal.ppat.1000781
- 738 41. Gardinassi LG, Garcia GR, Costa CHN, Costa Silva V, de Miranda Santos IKF.

Blood Transcriptional Profiling Reveals Immunological Signatures of Distinct States of Infection of Humans with *Leishmania infantum*. Acosta-Serrano A, editor. PLoS Negl Trop Dis. 2016;10: e0005123. doi:10.1371/journal.pntd.0005123

42. Zacarias DA, Rolão N, de Pinho FA, Sene I, Silva JC, Pereira TC, et al. Causes and consequences of higher *Leishmania infantum* burden in patients with kala-azar: a study of 625 patients. Trop Med Int Heal. 2017;22: 679–687. doi:10.1111/tmi.12877

43. Bogdan C, Donhauser N, Döring R, Röllinghoff M, Diefenbach A, Rittig MG. Fibroblasts as host cells in latent leishmaniosis. J Exp Med. 2000;191: 2121–2129. doi:10.1084/jem.191.12.2121

44. Paduch K, Debus A, Rai B, Schleicher U, Bogdan C. Resolution of Cutaneous Leishmaniasis and Persistence of *Leishmania major* in the Absence of Arginase 1. J Immunol. 2019;202: 1453–1464. doi:10.4049/jimmunol.1801249

45. Seyed N, Peters NC, Rafati S. Translating observations from Leishmanization into non-living vaccines: The potential of dendritic cell-based vaccination strategies against *Leishmania*. Front Immunol. 2018;9: 1–10. doi:10.3389/fimmu.2018.01227

46. Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, Brodskyn C, et al. Balance of IL-10 and interferon- γ plasma levels in human visceral leishmaniasis: Implications in the pathogenesis. BMC Infect Dis. 2005;5: 1–9. doi:10.1186/1471-2334-5-113

47. Frade AF, Oliveira LC de, Costa DL, Costa CHN, Aquino D, Van Weyenbergh J, et al. TGFB1 and IL8 gene polymorphisms and susceptibility to visceral leishmaniasis. Infect Genet Evol. 2011;11: 912–916.

doi:10.1016/j.meegid.2011.02.014

48. Carneiro MW, Fukutani KF, Andrade BB, Curvelo RP, Cristal JR, Carvalho AM, et al. Gene Expression Profile of High IFN- γ Producers Stimulated with *Leishmania braziliensis* Identifies Genes Associated with Cutaneous Leishmaniasis. McDowell MA, editor. PLoS Negl Trop Dis. 2016;10: e0005116. doi:10.1371/journal.pntd.0005116
49. Peruhype-Magalhães V, Martins-Filho OA, Prata A, Silva LDA, Rabello A, Teixeira-Carvalho A, et al. Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon- γ and interleukin-10 and low frequency of tumour necrosis factor- α + monocytes are hallmarks of active human visceral Leishmaniasis due to *Leishmania chagasi* infectio. Clin Exp Immunol. 2006;146: 124–132. doi:10.1111/j.1365-2249.2006.03171.x
50. Botana L, Ibarra-Meneses AV, Sánchez C, Castro A, Martin JVS, Molina L, et al. Asymptomatic immune responders to *Leishmania* among HIV positive patients. PLoS Negl Trop Dis. 2019;13: 1–14. doi:10.1371/journal.pntd.0007461
51. Horrillo L, Castro A, Matía B, Molina L, García-Martínez J, Jaqueti J, et al. Clinical aspects of visceral leishmaniasis caused by *L. infantum* in adults. Ten years of experience of the largest outbreak in Europe: what have we learned? Parasit Vectors. 2019;12: 359. doi:10.1186/s13071-019-3628-z
52. Ana Nilce S M, Adolfo G, Romero S, Samantha YOB, Lindoso AL, Elisa C, et al. Premature deaths by visceral leishmaniasis in Brazil investigated through a cohort study: A challenging opportunity? PLoS Negl Trop Dis. 2019;13: 1–18. doi:https://doi.org/10.1371/journal.pntd.0007841
53. Van Griensven J, van Henten S, Mengesha B, Kassa M, Adem E, Seid ME, et al. Longitudinal evaluation of asymptomatic *Leishmania* infection in HIV-infected

- 789 individuals in North-West Ethiopia: A pilot study. PLoS Negl Trop Dis. 2019;13:
790 30–45. doi:10.1371/journal.pntd.0007765
- 791 54. Diro E, Edwards T, Ritmeijer K, Fikre H, Abongomera C, Kibret A, et al. Long
792 term outcomes and prognostics of visceral leishmaniasis in hiv infected patients
793 with use of pentamidine as secondary prophylaxis based on CD4 level: A
794 prospective cohort study in Ethiopia. PLoS Negl Trop Dis. 2019;13: 1–17.
795 doi:10.1371/journal.pntd.0007132
- 796 55. Prestes-Carneiro LE, Spir PRN, Fontanesi M, Pereira Garcia KG, Silva FA Da,
797 Flores EF, et al. Unusual manifestations of visceral leishmaniasis in children: A
798 case series and its spatial dispersion in the western region of São Paulo state,
799 Brazil. BMC Infect Dis. 2019;19: 1–9. doi:10.1186/s12879-018-3652-1
- 800 56. Fontoura IG, Barbosa DS, de Andrade Paes AM, Santos FS, Neto MS, Fontoura
801 VM, et al. Epidemiological, clinical and laboratory aspects of human visceral
802 leishmaniasis (HVL) associated with human immunodeficiency virus (HIV)
803 coinfection: a systematic review – CORRIGENDUM. Parasitology. 2018;145:
804 1819–1819. doi:10.1017/S0031182018001166
- 805 57. Rezaei Z, Sarkari B, Dehghani M, Layegh Gigloo A, Afrashteh M. High frequency
806 of subclinical Leishmania infection among HIV-infected patients living in the
807 endemic areas of visceral leishmaniasis in Fars province, southern Iran. Parasitol
808 Res. 2018;117: 2591–2595. doi:10.1007/s00436-018-5949-9
- 809 58. Viana GM de C, da Silva MACN, Garcia JV de S, Guimarães HD, Arcos Júnior
810 GF, Santos AVA, et al. Epidemiological profile of patients co-infected with
811 visceral leishmaniasis and HIV/AIDS in northeast, Brazil. Rev Soc Bras Med Trop.
812 2017;50: 613–620. doi:10.1590/0037-8682-0494-2017
- 813 59. Orsini M, Canela JR, Disch J, Maciel F, Greco D, Toledo A, et al. High frequency

- 814 of asymptomatic *Leishmania* spp. infection among HIV-infected patients living in
- 815 endemic areas for visceral leishmaniasis in Brazil. *Trans R Soc Trop Med Hyg.*
- 816 2012;106: 283–288. doi:10.1016/j.trstmh.2012.01.008
- 817 60. Fukutani KF, Figueiredo V, Celes FS, Cristal JR, Barral A, Barral-Netto M, et al.
- 818 Serological survey of *Leishmania* infection in blood donors in Salvador,
- 819 Northeastern Brazil. *BMC Infect Dis.* 2014;14: 422. doi:10.1186/1471-2334-14-
- 820 422
- 821 61. Oryan A, Akbari M. Worldwide risk factors in leishmaniasis. *Asian Pac J Trop*
- 822 *Med.* 2016;9: 925–932. doi:10.1016/j.apjtm.2016.06.021
- 823 62. Grande E, Zucchetto A, Suligoi B, Grippo F, Pappagallo M, Viridone S, et al.
- 824 Multiple cause-of-death data among people with AIDS in Italy: A nationwide
- 825 cross-sectional study. *Popul Health Metr.* 2017;15: 1–12. doi:10.1186/s12963-
- 826 017-0135-3
- 827 63. Bruhn FRP, Morais MHF, Bruhn NCP, Cardoso DL, Ferreira F, Rocha CMBM.
- 828 Human visceral leishmaniasis: Factors associated with deaths in Belo Horizonte,
- 829 Minas Gerais state, Brazil from 2006 to 2013. *Epidemiol Infect.* 2018;146: 565–
- 830 570. doi:10.1017/S0950268818000109
- 831 64. Guedes DL, Medeiros Z, Da Silva ED, De Vasconcelos AVM, Da Silva MS, Da
- 832 Silva MAL, et al. Visceral leishmaniasis in hospitalized HIV-infected patients in
- 833 Pernambuco, Brazil. *Am J Trop Med Hyg.* 2018;99: 1541–1546.
- 834 doi:10.4269/ajtmh.17-0787
- 835 65. Braga L de S, Navasconi TR, Leatte EP, Skraba CM, Silveira TGV, Ribas-Silva
- 836 RC. Presence of anti-*leishmania* (*viannia*) *braziliensis* antibodies in blood donors
- 837 in the west-central region of the state of Paraná, Brazil. *Rev Soc Bras Med Trop.*
- 838 2015;48: 622–625. doi:10.1590/0037-8682-0043-2015

- 839 66. Monteiro DCS, Sousa AQ, Lima DM, Fontes RM, Praciano CC, Frutuoso MS, et
840 al. Leishmania infantum Infection in Blood Donors, Northeastern Brazil. Emerg
841 Infect Dis. 2016;22: 739–740. doi:10.3201/eid2204.150065
- 842 67. le Fichoux Y, Quaranta JF, Aufeuvre JP, Lelievre A, Marty P, Suffia I, et al.
843 Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors
844 living in an area of endemicity in southern France. J Clin Microbiol. 1999;37:
845 1953–7.
- 846 68. de Oliveira França A, Pompilio MA, Pontes ERJC, de Oliveira MP, Pereira LOR,
847 Lima RB, et al. Leishmania infection in blood donors: A new challenge in
848 leishmaniasis transmission? PLoS One. 2018;13: 1–13.
849 doi:10.1371/journal.pone.0198199
- 850 69. Khouri R, Vandamme AM. Virus genetic variability involvement in
851 transmissibility of HIV-1 immune activation and disease progression. Future Virol.
852 2015;10: 1259–1262. doi:10.2217/fvl.15.96
- 853 70. Araujo AF, Brites C, Monteiro-Cunha J, Santos LA, Galvao–Castro B, Alcantara
854 LCJ. Lower Prevalence of Human Immunodeficiency Virus Type 1 Brazilian
855 Subtype B Found in Northeastern Brazil with Slower Progression to AIDS. AIDS
856 Res Hum Retroviruses. 2010;26: 1249–1254. doi:10.1089/aid.2010.0068
- 857 71. Monteiro-Cunha JP, Araujo AF, Santos E, Galvao-Castro B, Alcantara LCJ. Lack
858 of High-Level Resistance Mutations in HIV Type 1 BF Recombinant Strains
859 Circulating in Northeast Brazil. AIDS Res Hum Retroviruses. 2011;27: 623–631.
860 doi:10.1089/aid.2010.0126
- 861 72. Santos LA, Monteiro-Cunha JP, Araújo AF, Brites C, Galvão-Castro B, Alcantara
862 LCJ. Detection of Distinct Human Immunodeficiency Virus Type 1 Circulating
863 Recombinant Forms in Northeast Brazil. J Med Virol. 2011;83: 2066–2072.

864 doi:10.1002/jmv

865 73. Chavez HH, Tran T-A, Dembele B, Nasreddine N, Lambotte O, Gubler B, et al.
866 Lack of Evidence for Prolonged Double-Long Terminal Repeat Episomal HIV
867 DNA Stability In Vivo. JAIDS J Acquir Immune Defic Syndr. 2007;45: 247–249.
868 doi:10.1097/QAI.0b013e3180415dc2

869 74. Santos EDS, Araújo AF, Galvão-Castro B, Alcantara LCJ. Diversidade genética
870 do vírus da imunodeficiência humana tipo 1 (HIV-1) em mulheres infectadas de
871 uma cidade do nordeste do Brasil. Rev Bras Ginecol e Obs. 2009;31: 609–614.
872 doi:10.1590/S0100-72032009001200006

873 75. Monteiro JP, Alcantara LCJ, de Oliveira T, Oliveira AM, Melo MAG, Brites C, et
874 al. Genetic variability of human immunodeficiency virus-1 in Bahia state,
875 Northeast, Brazil: High diversity of HIV genotypes. J Med Virol. 2009;81: 391–
876 399. doi:10.1002/jmv.21414

877 76. Hoffmann M, Pantazis N, Martin GE, Hickling S, Hurst J, Meyerowitz J, et al.
878 Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary
879 HIV-1 Infection. Wanstrom R, editor. PLOS Pathog. 2016;12: e1005661.
880 doi:10.1371/journal.ppat.1005661

881 77. Ipp H, Zemlin AE, Erasmus RT, Glashoff RH. Role of inflammation in HIV-1
882 disease progression and prognosis. Crit Rev Clin Lab Sci. 2014;51: 98–111.
883 doi:10.3109/10408363.2013.865702

884 78. Utay NS, Hunt PW. Role of immune activation in progression to AIDS. Curr Opin
885 HIV AIDS. 2016;11: 131–137. doi:10.1097/COH.0000000000000242

886 79. Kedzierska K, Crowe SM. Cytokines and HIV-1: Interactions and Clinical
887 Implications. Antivir Chem Chemother. 2001;12: 133–150.
888 doi:10.1177/095632020101200301

- 889 80. Kenway-Lynch CS, Das A, Lackner AA, Pahar B. Cytokine/Chemokine
890 Responses in Activated CD4+ and CD8+ T Cells Isolated from Peripheral Blood,
891 Bone Marrow, and Axillary Lymph Nodes during Acute Simian
892 Immunodeficiency Virus Infection. J Virol. 2014;88: 9442–9457.
893 doi:10.1128/JVI.00774-14
- 894 81. Mehla R. Chemokine Deregulation in HIV Infection: Role of Interferon Gamma
895 Induced Th1-Chemokine Signaling. J Clin Cell Immunol. 2013;04.
896 doi:10.4172/2155-9899.S7-004
- 897 82. Uday NS, Douek DC. Interferons and HIV Infection: The Good, the Bad, and the
898 Ugly. Pathog Immun. 2016;1: 107. doi:10.20411/pai.v1i1.125
- 899 83. Accornero P, Radrizzani M, Delia D, Gerosa F, Kurrle R, Colombo MP.
900 Differential Susceptibility to HIV-GP120–Sensitized Apoptosis in CD4+ T-Cell
901 Clones With Different T-Helper Phenotypes: Role of CD95/CD95L Interactions.
902 Blood. 1997;89: 558–569. doi:10.1182/blood.V89.2.558
- 903 84. Cummins NW, Badley AD. Mechanisms of HIV-associated lymphocyte apoptosis:
904 2010. Cell Death Dis. 2010;1: e99–e99. doi:10.1038/cddis.2010.77
- 905 85. Costa ASA, Costa GC, Aquino DMC de, Mendonça VRR de, Barral A, Barral-
906 Netto M, et al. Cytokines and visceral leishmaniasis: a comparison of plasma
907 cytokine profiles between the clinical forms of visceral leishmaniasis. Mem Inst
908 Oswaldo Cruz. 2012;107: 735–739. doi:10.1590/S0074-02762012000600005
- 909 86. Rodrigues V, Cordeiro-da-Silva A, Laforge M, Silvestre R, Estaquier J. Regulation
910 of immunity during visceral Leishmania infection. Parasit Vectors. 2016;9: 118.
911 doi:10.1186/s13071-016-1412-x
- 912 87. Sun H, Kim D, Li X, Kiselina M, Ouyang Z, Vandekerckhove L, et al. Th1/17
913 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral

914 Therapy. Silvestri G, editor. J Virol. 2015;89: 11284–11293.
 915 doi:10.1128/JVI.01595-15

916 88. Khouri R, Silva-Santos G, Dierckx T, Menezes SM, Decanine D, Theys K, et al.
 917 A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and
 918 apoptosis in healthy controls and Adult T-cell Leukemia patients.
 919 Oncoimmunology. 2018;7: e1426423. doi:10.1080/2162402X.2018.1426423

920 89. Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, et al.
 921 Fas-670 promoter polymorphism is associated to susceptibility, clinical
 922 presentation, and survival in adult T cell leukemia. J Leukoc Biol. 2008;83: 220–
 923 222. doi:10.1189/jlb.0407198

924

Figure 2 A

anti-SLA
1998-2013

16.27%	870
83.73%	4476

Figure 2 B

Figure 1

Figure 3 A

anti-SLA
2014-2015

Figure 3 B

anti-HSP70
2014-2015

Figure 3 C

anti-SLA

anti-HSP70

Figure 3 D

Figure 4 A

Figure 4 B

Figure 4 C

Figure 4 D

Figure 4 E

HIV untreated up

VL active disease

Gene Set Name

overlap

p-value

FDR

UP_BY_HBV_INFECTION

0.097

1.41E-17

4.65E-14

INTERFERON_RESPONSIVE_GENES

0.1

8.14E-13

8.96E-10

RESPONSE_TO_IFNG_UP

0.093

1.85E-12

1.52E-09

IFNB1_TARGETS

0.075

9.38E-12

6.19E-09

GRAFT_VERSUS_HOST_DISEASE_D7_UP

0.063

3.27E-11

1.35E-08

ANTIGEN_RESPONSE

0.025

1.30E-10

4.30E-08

BLISTER_CYTOTOXICITY_UP

0.044

7.56E-09

1.31E-06

GRAFT_VERSUS_HOST_DISEASE_35D_UP

0.043

8.62E-09

1.42E-06

Figure 6 A

HIV untreated up Leishmania exposed

Gene Set Name	overlap	p-value	FDR
IFNB1_TARGETS	0.37	1.04E-77	3.42E-74
INTERFERON_INDUCED_ANTIVIRAL_MODULE	0.36	4.53E-61	4.98E-58
INTERFERON_RESPONSIVE_GENES	0.39	1.80E-57	1.49E-54
IFNA_RESPONSE	0.61	6.84E-47	3.76E-44
INFLAMMATORY_RESPONSE_LPS	0.069	2.12E-43	8.75E-41
TNF_SIGNALING_UP	0.12	1.36E-16	1.02E-14
INFLAMMATORY_RESPONSE_LPS_UP	0.035	3.27E-15	2.30E-13
RESPONSE_TO_LPS_WITH_MECHANICAL_VENTILATION	0.082	7.35E-15	5.06E-13

Figure 6 B

Leishmania active disease UP

Gene	logFC	p value	FDR
CCL2	-0.14	0.15	0.47
CCL5	0.38	0.20	0.52
CXCL8	-0.16	0.06	0.32
CXCL9	ND	NA	NA
CXCL10	0.81	0.00003	0.0027
STAT1	1.18	0.00002	0.0024

Leishmania-exposed UP

Gene	logFC	p value	FDR
CCL2	0.04	0.21	0.89
CCL5	-0.11	0.39	0.95
CXCL8	-0.12	0.2	0.890
CXCL9	ND	NA	NA
CXCL10	0.14	0.0089	0.59
STAT1	0.45	0.011	0.62

Figure 6 C

HIV untreated UP

Gene	logFC	p value	FDR
CCL2	0.25	0.0019	0.10
CCL5	0.01	0.96	0.99
CXCL8	-0.60	0.0021	0.10
CXCL9	0.03	0.017	0.27
CXCL10	0.15	0.030	0.32
STAT1	0.15	0.030	0.32

Correlation HIV viral load set point

Gene	Spearman's R	p value	FDR
CCL2	0.31	0.00047	0.04
CCL5	0.16	0.076	0.29
CXCL8	-0.13	0.14	0.55
CXCL9	0.3	0.00052	0.08
CXCL10	0.43	6.23E-07	6.90E-04
STAT1	0.5	6.33E-09	3.82E-06

Figure 6 D

Figure 4 F

Figure 5 A

Figure 5 B

Figure 5 C

Figure 5 D

Figure 5 E

Figure 5 F

Figure 5 G

Figure 5 H

Figure 5 I

Figure 5 J